Navigation Links
DiObex Inc. to Present at BIO Mid-America Venture Forum
Date:9/18/2007

SAN FRANCISCO, Sept. 18 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that CEO David Cory will deliver a corporate presentation at the upcoming Biotechnology Industry Organization (BIO) Mid-America Venture Forum in Milwaukee, Wisconsin. The DiObex presentation will take place on Wednesday, September 26th at 1:30 p.m. at the Hyatt Regency Hotel in Room A.

About DiObex

DiObex, Inc. is a San Francisco-based biotechnology company founded to develop novel products for the treatment of metabolic diseases. DiObex has two product candidates in Phase 2 clinical development. DIO-901 (very low dose glucagon) is in development as an extended release subcutaneous formulation for reducing or preventing insulin-induced hypoglycemia in type 1 diabetes mellitus. DIO-901 has received Fast Track status from the Food and Drug Administration. DIO-902 (levdexketoconazole) is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease. For more information, visit http://www.diobex.com.


'/>"/>
SOURCE DiObex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... PharmAthene, Inc.,(NYSE: PIP ) a biodefense ... announced today that its financial results,for the third ... November 13,2008., PharmAthene management will be hosting ... financial results. The call is scheduled to begin ...
... New Facility in Oregon Will Help Ramp Up New Corn Hybrids Faster. ... ... announced plans to construct a parent seed corn production facility in Hermiston, ... Pioneer Hi-Bred is taking to ensure it meets rising demand for ...
... researchers are showing that Microsoft SQL ... up to 1 petabyte., REDMOND, Wash., Nov. ... its data management and business,intelligence platform, Microsoft SQL ... software to scale new heights in data warehousing,and ...
Cached Biology Technology:PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008 2DuPont Expands Seed Production Capacity to Meet Growing Demand for Seed, Grain 2DuPont Expands Seed Production Capacity to Meet Growing Demand for Seed, Grain 3Could Database Software Help Cure Alzheimer's and Save the Earth? 2Could Database Software Help Cure Alzheimer's and Save the Earth? 3
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... QS-21A, a medicinally important molecule that helps the body ... University of Illinois at Urbana-Champaign. , In clinical trials, ... immune response in vaccine therapies against aggressive diseases such ... HIV-1 and malaria. An extract from the bark of ...
... have shown that a commonly used procedure to remove ... does not improve patient outcomes. , The procedure, called ... angioplasty in vein grafts and stenting in carotid arteries. ... the Journal of the American Medical Association, found that ...
... cells, the immune system's sentinels, patrol the labyrinthine blood ... tissue damage and demonstrate a dogged behavior not seen ... show that NKT cells crawl along vessel walls, even ... receive a chemical signal to unleash an immune-system assault ...
Cached Biology News:Columbia study shows widely used artery clearing device does not help patients during heart attack 2Natural Killers Could Lead to New Hepatitis Treatments 2Natural Killers Could Lead to New Hepatitis Treatments 3Natural Killers Could Lead to New Hepatitis Treatments 4
... Gene silencing experiments often call for ... NeoFX Transfection Agent refines siRNA transfection ... NeoFXs lipid-based formulation can be used ... they are subcultured without increased ...
Kit for BASE20/50 dual control unit, includes mounting plate, HOLDER50T, HEATERPAD50, SRTDX temperature probe(s)....
... CHEMICON® CaspaTag™ Pan-Caspase In Situ Assay Kit ... active caspases in cells undergoing apoptosis. The ... for use in diagnostic or therapeutic procedures. ... use a novel approach to detect active ...
... nM is available for in vivo ... in: Z. Hassani, G.-F. Lemkine, P. Erbacher, ... B.-A. Demeneix. Lipid-mediated siRNA delivery down regulates ... at picomolar levels. J. Gene Med., 2005, ...
Biology Products: